BioSpace News Archive

Takeda will develop soticlestat, a first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), as a potential treatment for developmental and epileptic encephalopathies.

Bionauts™, a novel treatment modality that uses remote-controlled microscale robots to deliver biologics, nucleic acids, or small molecule therapies to precise areas of the brain, has the potential to go where no therapy has gone before, opening up new pathways in the fight against devastating CNS disorders like gliomas and Huntington’s disease.

Gastrointestinal and autoimmune company Arena Pharmaceuticals announced mixed topline results for the Phase IIb trial of its oral cannabinoid receptor type 2 (CB2) agonist olorinab.

Across the Pharm Country Hotbed, the agency has provided hundreds of millions of dollars to universities, research institutes and pharmaceutical companies.

Century Therapeutics received a $160 million infusion of cash to advance the company’s pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies for cancer.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

The study of VIR-7831, which is a dual-action SARS-CoV-2 monoclonal antibody, was recommended to be closed to enrollment by an independent data monitoring board, stating that “there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit.”

GE Research selected DNA Script to join a collaboration working on a rapid response, mobile platform to develop on-demand production of nucleic acid-based vaccines and therapies related to biological threats.

Recent research suggests that it may be possible to categorize GBM into different subtypes based on the underlying biological mechanisms driving tumor development and growth.

STI-2099 is a formulation of its antibody against COVID-19 that can be taken in a nasal spray. It is also evaluating the antibody in an intravenous form (STI-2020) in a Phase I trial.